Overview

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia.

Phase:

Phase 2

Details

Lead Sponsor:

University of Pittsburgh

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

gamma-Aminobutyric Acid